Westfield Capital Management
PCVX icon

Westfield Capital Management’s Vaxcyte PCVX Stock Holding History

Westfield Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144M Sell
2,472,428
-1,173,710
-32% -$63.7M 0.47% 61
2026
Q1 		$212M Buy
3,646,138
+106,421
+3% +$5.78M 0.89% 19
2025
Q4 		$163M Sell
3,539,717
-192,998
-5% -$8.63M 0.68% 32
2025
Q3 		$134M Buy
3,732,715
+663,817
+22% +$22M 0.56% 44
2025
Q2 		$99.8M Buy
3,068,898
+913,761
+42% +$30M 0.42% 69
2025
Q1 		$81.4M Sell
2,155,137
-411,622
-16% -$32.9M 0.4% 71
2024
Q4 		$210M Buy
2,566,759
+826,885
+48% +$82.1M 0.91% 19
2024
Q3 		$199M Sell
1,739,874
-189,474
-10% -$17.1M 0.9% 20
2024
Q2 		$146M Buy
1,929,348
+343,253
+22% +$23.4M 0.72% 27
2024
Q1 		$108M Buy
1,586,095
+130,502
+9% +$9.04M 0.57% 46
2023
Q4 		$91.4M Buy
1,455,593
+451,677
+45% +$23.5M 0.53% 60
2023
Q3 		$51.2M Buy
+1,003,916
New +$49.5M 0.35% 114

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Westfield Capital Management's PCVX Position: Q2 2026 in Review

Westfield Capital Management reduced its Vaxcyte (PCVX) stake by 32% in Q2 2026, selling an estimated $63.7M and leaving 2,472,428 shares worth $144M. The position accounts for 0.47% of the portfolio, ranked #61.

Westfield Capital Management first reported a position in PCVX in Q3 2023 and has held it in 12 quarters since. The position peaked at $212M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Westfield Capital Management held 2,472,428 shares of Vaxcyte worth $144M as of Q2 2026.
  • Westfield Capital Management sold 1,173,710 Vaxcyte shares in Q2 2026, an estimated $63.7M.
  • Vaxcyte made up 0.47% of Westfield Capital Management's portfolio in Q2 2026, its #61 holding.
  • Westfield Capital Management first reported a position in Vaxcyte in Q3 2023 and has held it in 12 quarters since.
  • Westfield Capital Management's Vaxcyte position peaked at $212M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.